Table 6 Decision to start with one antifibrotic treatment option and not the other
Total (n = 44) | Pirfenidone First (n = 21) | Nintedanib First (n = 23) | |
|---|---|---|---|
It was because of how effective the treatment is | 34% | 33% | 35% |
It had to do with side effects: nausea, vomiting, loss of appetite | 34% | 38% | 30% |
It had to do with side effects: diarrhea | 20% | 24% | 17% |
It had to do with side effects: photosensitivity and rash | 20% | 10% | 30% |
Another reason (please specify) | 18% | 29% | 9% |
It had to do with dosing and managing the medication logistics | 16% | 5% | 26% |
Because of cost/out of pocket expense and/or insurance coverage | 18% | 24% | 13% |